Care este prețul pentru Philogen S.p.A. (PHIL)

Prețul pentru Philogen S.p.A. (PHIL) este $27.76

Care este capitalizarea de piață pentru Philogen S.p.A. (PHIL)

Capitalizarea de piață pentru Philogen S.p.A. (PHIL) este $801.60M

Philogen S.p.A. (PHIL) Dividende

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.

An	Dividend (ajustat pentru split de acțiuni)	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Dividend (ajustat pentru split de acțiuni)

Schimbă

Nu sunt suficiente date pentru perioada selectată.

An	Dividend	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Dividend

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Număr de plăți de dividende	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Companie

Număr de plăți de dividende

Țara